---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005777"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:23:21.581415+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director

## Summary
- Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.
- Eric Poma, Ph.D. named CEO and Class I director effective April 22, 2025; previously CEO of Molecular Templates (MTEM).
- Poma receives $535k base salary, target bonus up to 50% of base, and option grant for 726,412 shares vesting over 4 years.
- Camaisa gets $500k separation over 12 months, COBRA for 12 months, $10k/month transition pay, plus possible incentives through Dec 2026.
- James Schoeneck appointed Chairman; board size increased from 5 to 6 members.

## SEC filing metadata
- accession: 0001641172-25-005777
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005777
- JSON: https://secwatch.observer/filing/0001641172-25-005777.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005777.txt

## Key facts
- Executive change
  Eric Poma was appointed as Class I Director at Calidi Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm
- Executive change
  Allan Camaisa resigned as Chairman of the Board at Calidi Biotherapeutics, Inc..
  - Action: resigned
  - Role: Chairman of the Board
  source text: Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm
- Executive change
  Eric Poma was appointed as Chief Executive Officer at Calidi Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm
- Executive change
  Allan Camaisa resigned as Chief Executive Officer at Calidi Biotherapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.